REG - Arecor Therapeutics - Grant of Options, PDMR Dealing

Arecor TherapeuticsAnnouncement

25/11/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211125:nRSY5231Ta&default-theme=true

RNS Number : 5231T  Arecor Therapeutics PLC  25 November 2021

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

 

Grant of Options, PDMR Dealing

 

Cambridge, UK, 25 November 2021: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier
lives, announces that on 24 November 2021, it granted a total of 87,500
options under the Company's All Employee Share Ownership Plan ("AESOP
Options") and 75,000 options under the Company's Long Term Incentive Plan
("LTIP Options") over new ordinary shares of 0.1 pence each in the Company
("Ordinary Shares").

The AESOP Options, which vest after 12 months, are exercisable at £4.15,
subject to continuous employment, and are exercisable up to ten years from the
date of grant. The LTIP Options are exercisable at £0.01, subject to
continued employment and the meeting of certain performance conditions, and
are exercisable up to ten years from the date of grant. 40,000 of the AESOP
Options and 75,000 of the LTIP Options were granted to Lindsey Foulkes, Chief
Operating Officer and a PDMR of the Company. Following this grant of options,
Lindsey Foulkes holds 115,000 options over Ordinary Shares of the Company.

The notifications below, made in accordance with the requirements of the
Market Abuse Regulation, provide further detail.

 

For further information, please contact:

 

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)

 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:sarah.howell@arecor.com)

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:info@arecor.com)

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)

 Panmure Gordon (UK) Limited                      Tel: +44 (0) 20 7886 2500

 (NOMAD and Broker)

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray          Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat ™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com/)

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

       Details of the person discharging managerial responsibilities/person closely
       associated
 a)    Name:                                                         Lindsey Foulkes
 2.    Reason for the notification
 a)    Position/status:                                              Chief Operating Officer
 b)    Initial notification/Amendment:                               Initial notification
 3.    Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name:                                                         Arecor Therapeutics PLC
 b)    LEI:                                                          98450093D12I3A8DDD58
 4.    Details of the transaction(s): section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the financial instrument, type of instrument:  Ordinary shares of 1 pence each

       Identification code:                                          GB00BMWLM973
 b)    Nature of the transaction:                                    Grant of options over ordinary shares
 c)    Price(s) and volume(s):

Exercise Price(s)  Volume(s)
                                                                     £0.01              75,000
                                                                     £4.15              40,000

 

 d)    Aggregated information:

       · Aggregated volume:                                          115,000

       · Price:                                                      N/A
 e)    Date of the transaction:                                      24 November 2021
 f)    Place of the transaction:                                     Outside of a trading venue

 

 

d)

Aggregated information:

· Aggregated volume:

· Price:

 

115,000

N/A

e)

Date of the transaction:

24 November 2021

f)

Place of the transaction:

Outside of a trading venue

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBIBBTMTJTTMB